1. "2023"
Formats
  1. Journal Article (2318)
  2. Meeting Abstract (1954)
  3. Review (629)
  4. Editorial (353)
  5. Book Section (144)
  6. Research Letter (101)
  7. Guidelines (97)
  8. Correspondence (91)
  9. Miscellaneous (57)
  10. Conference Paper (50)
  11. Book Whole (10)
Groups
  1. Department of Medicine (2451)
  2. Solid Tumor Oncology Division (1380)
  3. Sloan Kettering Institute Postdocs (1151)
  4. Hematologic Malignancies, Division of (1038)
  5. GSK Faculty (1016)
  6. Surgery (930)

More Groups

People
  1. Saad Usmani (123)
  2. Sergio Giralt (104)
  3. Miguel-Angel Perales (101)
  4. Gilles Salles (97)
  5. Gunjan Shah (85)
  6. Michael Scordo (81)

More People

Years
  1. 2023 (5804)
Publications
  1. Journal of Clinical Oncology (553)
  2. Blood (402)
  3. Annals of Oncology (154)
  4. Annals of Surgical Oncology (120)
  5. International Journal of Radiation Oncology, Biology, Physics (116)
  6. Laboratory Investigation (88)

More Publications

Publishers
  1. Elsevier Inc. (762)
  2. American Society of Clinical Oncology (606)
  3. American Society of Hematology (478)
  4. Springer (375)
  5. Oxford University Press (359)
  6. Nature Publishing Group (339)

More Publishers

Results (5804)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prognostic value of neutrophil-to-lymphocyte ratio and lymphopenia in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with [177Lu]Lu-PSMA-617: VISION post hoc analysis
    Meeting Abstract

    Wei, X. X.; Chi, K. N. N.; de Bono, J. S.; Fizazi, K.; Krause, B.; Herrmann, K.; Rahbar, K.; Tagawa, S. T.; Morris, M. J.; Meisel, A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Cancer premium: Explaining differences in prices for cancer vs non-cancer drugs with efficacy and epidemiological endpoints in the US, Germany, and Switzerland
    Meeting Abstract

    Serra-Burriel, M.; Perényi, G.; Laube, Y.; Mitchell, A.; Vokinger, K. N.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Kelly, W.; Danila, D.; Lin, C. C.; Lee, J. L.; Matsubara, N.; Ward, P.; Armstrong, A. J.; Pook, D.; Kim, M.; Dorff, T.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy of niraparib and abiraterone acetate plus prednisone (NIRA+AAP) in homologous recombination repair gene-altered (HRR+) metastatic castration-resistant prostate cancer (mCRPC) by tissue and/or plasma assays in the MAGNITUDE trial
    Meeting Abstract

    Attard, G.; Sandhu, S. K.; Rathkopf, D.; Castro, E.; Saad, M.; Smith, M. R.; Small, E. J. J.; Olmos, D.; Gomes, A. J. P. D. S; Roubaud, G.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Association of health-related quality of life with efficacy outcomes in the VISION study of patients with metastatic castration-resistant prostate cancer
    Meeting Abstract

    Morris, M. J.; Armstrong, A. J.; Chi, K. N. N.; de Bono, J. S.; Herrmann, K.; Krause, B.; Rahbar, K.; Sartor, O.; Tagawa, S. T.; Nagarajah, J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Phase I/II trial of oral EPI-7386 in combination with enzalutamide (enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects: Current phase I (PI) results
    Meeting Abstract

    Laccetti, A. L.; Chatta, G.; Kyriakopoulos, C.; Iannotti, N.; Hotte, S. J.; Markowski, M. C.; Pili, R.; Vuky, J.; Zhang, J.; Saad, F.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Simulation training for compassionate extubation in the pediatric intensive care unit
    Meeting Abstract

    Fernandez, N.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)
    Meeting Abstract

    Schram, A.; Macarulla, T.; Cleary, J.; Neuzillet, C.; Arnold, D.; Reiss, K. A.; Bekaii-Saab, T.; Rodon, J.; Goto, K.; Rha, S. Y.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • A novel endoscopic ultrasound guided extended-release siRNA implant targeting KRASG12D/V in localized pancreatic cancer
    Meeting Abstract

    Varghese, A. M.; Golan, T.; Schattner, M.; Ang, C.; Gutierrez, M.; Passhak, M.; Geva, R.; Yarom, N.; Ligresti, R.; Khamaysi, I.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Health-related quality of life with nalirifox versus nabpaclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): EORTC QLQ-C30 results from the NAPOLI 3 trial
    Meeting Abstract

    Melisi, D.; Macarulla, T.; de la Fouchardiere, C.; Cid, R. A. P.; Chandana, S.; Dean, A.; Kiss, I.; Lee, W.; Goetze, T. O.; Van Cutsem, E.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save